Articles
-
3 weeks ago |
thepharmaletter.com | Ángel Galindo
In Latin America, the average percentage of the public budget for health is 12.75%, half of what is allocated by the 38 countries that make up the Organization for Economic Cooperation and Development (OECD), which on average is 24.5%. Added to this reality is the fact that Latin America is more dependent on private spending on health, especially on out-of-pocket spending.
-
Feb 21, 2025 |
dialnet.unirioja.es | Pedro Lago |Ángel Galindo |Helenio Ferrer |Ángel Goyenechea
Ayuda Buscar en la ayuda Buscar en la ayuda Casos de poliomielitis paralítica asociada a la vacuna oral antipoliomielítica en Cuba (1963-2006) Pedro Más Lago [1] ; Helenio Ferrer [1] ; Ángel Goyenechea [1] ; Ángel Galindo [1] ; Luis Sarmiento [1] ; Magilé Fonseca [1] ; Luis Morier [1] ; Rosa Palomera [1] [1] Instituto de Medicina Tropical Pedro Kourí Localización: Revista Cubana de Higiene y Epidemiología, ISSN-e 1561-3003, Vol. 46, Nº. 2, 2008 Idioma: español Títulos paralelos: Cases of...
-
Feb 10, 2025 |
dialnet.unirioja.es | Ángel Calvo Valcárcel |Ángel Galindo |Calvo Valcárcel |Carrasco Martín
Ayuda Buscar en la ayuda Buscar en la ayuda Estrategias innovadoras para optimizar la fertilización del cereal de invierno: resultados de ensayos "on farm" Ángel Calvo [1] ; Isarael Carrasco [1] ; Ángel Maresma [1] [1] Departamento I+D. Eurochem Agro Iberia, S.L. Localización: Tierras: Agricultura, ISSN-e 2696-3752, ISSN 1889-0776, Nº. 336, 2025, págs.
-
Jan 16, 2025 |
thepharmaletter.com | Ángel Galindo
Despite the strategies and programs that have been implemented to bring effective and equitable access to new medicines and technologies that provide equal or similar opportunities for citizens, regardless of their country, the reality is very different in Latin America, writes The Pharma Letter's local correspondent.
-
Nov 28, 2024 |
thepharmaletter.com | Ángel Galindo
The waiting time for Latin American patients with cancer, central nervous system disorders or rare diseases can take up to 4.75 years from the time a drug receives approval from global health authorities such as the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA), until it is approved by their local authority and is available on the market, writes The Pharma Letter's local correspondent.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →